NEW ATAI-Logo_Primary.png
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
05 mai 2022 15h19 HE | atai Life Sciences
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq:...
NEW ATAI-Logo_Primary.png
atai Life Sciences legt Finanzergebnisse für das erste Quartal 2022 vor
04 mai 2022 14h10 HE | atai Life Sciences
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen im klinischen Stadium, das anstrebt, die Behandlung von psychischen...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Announce First-Quarter 2022 Financial Results
04 mai 2022 04h00 HE | atai Life Sciences
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
atai Life Sciences ist Teilnehmer der im April stattfindenden Investorenkonferenz
20 avr. 2022 12h04 HE | atai Life Sciences
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen für den klinischen Bereich, das sich der Aufgabe verschrieben hat,...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in Upcoming April Investor Conference
19 avr. 2022 12h26 HE | atai Life Sciences
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
30 mars 2022 06h59 HE | atai Life Sciences
–   Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
23 mars 2022 06h59 HE | atai Life Sciences
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in Upcoming March Investor Conferences
21 mars 2022 13h08 HE | atai Life Sciences
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
atai Impact spendet an die Multidisciplinary Association for Psychedelic Studies (MAPS), um deren Pionierarbeit in der psychedelischen Medizin zu unterstützen
16 févr. 2022 17h47 HE | atai Life Sciences
- Führende gemeinnützige und kommerzielle Organisationen der psychedelischen Wissenschaft teilen die Vision von der Heilung psychischer Erkrankungen - Die Spende kommt von atai Impact, dem...
NEW ATAI-Logo_Primary.png
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
16 févr. 2022 06h59 HE | atai Life Sciences
- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions - Donation is from atai Impact, the philanthropic arm of mental health...